Rottapharm|Madaus, an italian success story
Passion for research and courage to take risks: these are the merits of Luigi Rovati, professor of pharmacology at the University of Pavia, who in 1961 decided to leave his academic career to create a small laboratory of independent research: Rotta Research Laboratorium. To this day, Rottapharm|Madaus has continued to grow and has become what is now, a Group located in over 85 countries in the world with over 2000 employees.
A flexible, cutting-edge company, constantly devoted to the frontline of health and prevention where it has, as of today, achieved many goals.
Research is our mission
The field of research is above all the undisputed true mission of the company, declared since its early beginnings. The traditional therapeutic osteoarticular and gastrointestinal areas were extended with the years to include gynaecology, urology, cardiology and the therapies of the respiratory tract and central nervous systems.
Rottapharm can boast a rich portfolio of original molecules and drugs, discovered and patented by its own R&D department. From the original glucosamine sulfate, an essential molecule in the treatment of osteoarthritis, to proglumetacina, a non-steroid anti-inflammatory drug, up to the launching of the first transdermal active matrix patch with estradiol an innovative transdermal releasing system for hormone replacement therapy in menopause. And research has not stopped: presently, only in the ethical pharmaceutical sector, Rottapharm|Madaus has over 13 projects in its pipeline.
A natural evolution: from debuting in personal care …
Today Rottapharm|Madaus is not only a pharmaceutical company.
With the acquisition, in 1999, of the brands Saugella and Babygella the group entered the sector of personal care . From then on, the same philosophy at the foundation of Rottapharm's pharmaceutical production has been applied to personal care: constant investments in research, rigours in productive standards, natural and highly selected raw materials, cutting-edge technologies in the production plants.
And the same strategic choice was shown some years later (2005) with the acquisition of the Biochimici PSN, an Italian company specialized in pharmaceutical dermocosmesis.
Nowadays, the Group boasts an undisputed leadership position in pharmaceutical personal care.
… to the development of nutraceuticals …
Worthy of note is Rottapharm|Madaus’s role in the field of nutraceuticals. With the launching of Estromineral, in 2001, the Group officially entered the market of dietary supplements. Estromineral– a dietary supplement with Soy Isoflavones for the treatment of menopause symptomatology – shortly became a pharmacy top seller. Today, thanks to the constant investment in research and development and an aimed extension of the line (with Estromineral Serena in 2002, Estromineral FIT in 2004 and Estromineral Lipid in 2010), Estromineral is the product line for the natural treatment of menopause most sold in italian pharmacies. In parallel, Rottapharm’s know how in cardiology and rheumatology has led to the launching of new nutraceutics: Armolipid (natural cardiovascular protection, followed by Armolipid Plus and, in 2011, by Armolipid Prev) and Fortilase (a dietary supplement with bromeline, endowed with anti-inflammatory and anti-edemic properties). In addition to these products, there are the historical solar dietary supplements of Carovit line (that entered Rottapharm’s products portfolio after the acquisition of Biochimici PSN) for the systemic preparation of the skin to photo-exposure and Biomineral for systemic hair care.
… always following the "natural" stream
With the acquisition of the German Madaus Pharma, specialized in the production of natural pharmaceutics, Rottapharm strengthened a route already undertaken by many of its brands: from natural origin to active principle. Always monitoring prevention and without straying from the rigorous scientific standards that have always characterized all its activities, Rottapharm|Madaus pursues its path towards an ampler concept of health, one which combines chemistry progress with the phitotherapic tradition.